Search clinical trials for: GLPG3067 oral suspension

Total 9049 results

Galapagos NV

Completed

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Healthy

Belgium
Galapagos NV

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Healthy

Belgium
Galapagos NV

Completed

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Cystic Fibrosis

Belgium
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1205

Healthy

Belgium
reMYND

Terminated

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Alzheimer Disease

Netherlands, Spain
Glock Health, Science and Research GmbH

Completed

G-PUR® for Reduced Lead Bioavailability

Lead Exposure

Austria
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

Healthy Subjects | Pharmacokinetics | Tolerability | Safety

United Kingdom
Vanda Pharmaceuticals

Completed

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Healthy

United States
Galapagos NV

Completed

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Healthy

United Kingdom
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

Cardiovascular Disease | Healthy Male Subjects

United Kingdom
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)

Systemic Lupus Erythematosus

United States, Spain, Bulgaria, France, Georgia, Puerto Rico, Argentina, Poland, Hungary, Germany, Chile, Peru
Vifor Fresenius Medical Care Renal Pharma
Tigermed Consulting Co., Ltd

Recruiting

Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects (Patiromer JADE)

Renal Insufficiency, Chronic | Hyperkalemia

China
Vifor Pharma, Inc.

Terminated

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia (EMERALD)

Hyperkalemia

United States, Bulgaria, Canada, Georgia, Germany, Poland, Ukraine
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Healthy

Canada
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Vanda Pharmaceuticals

Recruiting

Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

Sleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological Disorder

United States
Galapagos NV

Terminated

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Healthy

Netherlands
AstraZeneca
Quotient Sciences

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

Cardiovascular Disease

United Kingdom
Relypsa, Inc.

Terminated

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

Hyperkalemia

United States
Relypsa, Inc.

Completed

Patiromer With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Hyperkalemia

United States
Galapagos NV

Recruiting

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)

Dermatomyositis

United States, Belgium, Italy, Chile, Spain, Poland, United Kingdom, Bulgaria, Romania, Colombia, Croatia, Czechia, France, Argentina
Galapagos NV

Completed

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Healthy

Belgium
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Poland, Slovakia, Bulgaria
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Galapagos NV

Completed

First-in-Human Single and Multiple Dose of GLPG1690

Healthy

Belgium
Relypsa, Inc.

Completed

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) (OPAL)

Chronic Kidney Disease (CKD) | Hyperkalemia (HK)

United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine
Noxopharm Limited

Withdrawn

A Study of Safety and Tolerability of NOX66 in Healthy Volunteers

Healthy Volunteers

Australia
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants

Healthy

United States
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Galapagos NV

Completed

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Healthy

Belgium
Steno Diabetes Center Copenhagen
Zealand University Hospital; AstraZeneca

Unknown

The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia (ZIRCUS)

Type 2 Diabetes Mellitus With Kidney Complications

Denmark
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Hivih
Venn Life Sciences

Completed

Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.

Healthy

United Kingdom
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Teva Pharmaceuticals USA

Completed

Cefdinir for Oral Suspension 250 mg/5mL, Fasting

Healthy

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Teva Pharmaceuticals USA

Completed

Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting

Healthy

United States
Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
Teva Pharmaceuticals USA

Completed

Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

Healthy

United States
Humanetics Corporation
National Institute of Allergy and Infectious Diseases (NIAID); NYU Langone...

Recruiting

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

COVID-19 | Pulmonary Fibrosis | Long COVID | Post-acute Respiratory Complications of COVID-19

United States
GlaxoSmithKline

Completed

Amoxicillin Bioequivalence Study Brazil - Fast

Infections, Bacterial

Brazil
Sandoz

Completed

Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

Infections
Teva Pharmaceuticals USA

Completed

Cefprozil for Oral Suspension 250 mg/5 mL, Fasting

Healthy

United States
The Affiliated Hospital of Qingdao University

Completed

Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension

Healthy Subjects

China
Sandoz

Completed

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 250mg/5 ml Oral Suspension Fasting Conditions

Healthy
Applied Therapeutics, Inc.

Active, not recruiting

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency (INSPIRE)

Hereditary Neuropathy Caused by SORD Deficiency

United States, United Kingdom, Czechia, Italy
Columbia University

Active, not recruiting

Inulin for Infections in the Intensive Care Unit

Sepsis | Critical Illness | Nutrition Disorders | Antibiotic Resistant Infection | Nosocomial Infection | Pathogen Transmission

United States

3

Subscribe